ABSTRACT
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High abundance of CD271+ multipotential stromal cells (MSCs) in intramedullary cavities of long-bones
Our findings therefore reveal that the intramedullary cavity of the human femur is a depot of MSCs, which, although closely associated with fat, have a differentiation profile equivalent to ICBM. This anatomical site is frequently accessed by the orthopaedic/trauma surgeon and aspiration of the intramedullary cavity represents a 'low-tech' method of harvesting MSCs for regenerative therapies and research.
INTRODUCTION
The iliac crest bone marrow aspirate (ICBMA) was the first source from which multipotential stromal cells (MSCs), also termed mesenchymal stem cells, were isolated [1] . This anatomical site has become the most frequently accessed in harvesting MSCs for bone tissue engineering and is generally accepted as the 'gold-standard'. Whilst this source is readily accessible and has good handling properties it has a low frequency of MSCs (0.001-0.01%) [1] . This is of significance as many regenerative medicine uses of MSCs including putative bone repair applications require large cell numbers [2] [3] [4] . High MSC yields can be achieved by in vitro culture with relative ease, with a 1000-fold increase in numbers within 2-3 weeks [5] . However, this results in daughter cells that have reduced differentiation capacity [5] and impaired cell function including gradual accumulation of senescence-related markers [6, 7] and increased potential for transformation [8] . This process is also time-inefficient, expensive and requires industrial-scale good-manufacturing practice (GMP)-compatible cell expansion facilities and a two-stage surgery for tissue procurement and implantation [9] .
Due to these factors there is a need to find alternative MSC sources where there is a potentially larger yield of cells. Initial techniques involved the development of devices to concentrate MSCs from large volumes of ICBM aspirate by centrifugation [10] -and such devices are available in the clinic. The implantation of 50,000 uncultured MSCs/CFU-Fs by concentrating up to 300 ml of ICBMA has shown an improvement of fracture healing in one study [10] . However, it is not always possible to obtain such large amounts of ICBMA. The enzymatic digestion of adiposerich connective tissues such as fat has been proposed as an alternative strategy, with authors reporting the liberation of 500-fold more MSCs per gram of tissue when compared with ICBMA [11] . Lipoaspiration however cannot be performed for every orthopedic patient and the "quality" of lipoaspirate-derived MSCs for bone repair applications remains debatable [12] [13] [14] [15] [16] [17] .
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Multipotential stromal cells have previously been shown to be present in the intramedullary cavity of long bones in humans [18] . However, this has been largely ignored as a source of MSCs for bone regeneration. In contrast, the harvesting of long-bone BM has been practiced on rat [19] , mouse [20] , rabbit [21] [22] [23] and pig [24, 25] and is probably the most prevalent research method of isolating MSCs from animals. Analogous to other adipose-rich tissues, it may be hypothesized to the intra-medullary (IM) contents of long bones contain large numbers of MSCs. Unlike peripheral fat tissues, the MSCs are present in a bone related micro-environment and may potentially exhibit good intrinsic osteogenic capabilities. This is supported by early pioneering findings documenting a strong in vivo osteogenic capacity of adipogenic marrow cells [23] .
This study explored the aspirated contents from the IM cavities of long bones, which are frequently accessed by the trauma/orthopaedic surgeon, as a source of MSCs in comparison to the 'gold standard' iliac crest aspirated source. We used colony-forming fibroblast (CFU-F) assay [26] and flow cytometry for CD45 -/low CD271 + fraction [27] [28] [29] to enumerate MSCs and compared their frequency with donor-matched ICBM aspirates. We also used functional in vitro assays for MSC expansion and differentiation, to demonstrate that MSCs from IM cavities of long bones were equal or superior to their ICBMA counterparts. These findings should permit the development of novel one-step MSC harvesting procedures for bone repair augmentation in fracture patients.
MATERIALS & METHODS
Subjects & specimen collection:
Approval for these studies was obtained from the Leeds Teaching Hospital NHS trust ethics committee, with all patients providing informed consent. For the purpose of this research, iliac crest bone marrow aspirate (ICBMA) was obtained from 11 acute trauma patients, 11 patients with post-traumatic disorders, 15 patients with long bone (tibia/femur) non-union fractures and A C C E P T E D M A N U S C R I P T
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6 healthy controls ( The LBFBM contents were aspirated via the greater trochanter, which was opened surgically, prior to the harvest of bone graft using the reamer-irrigator-aspirator (RIA) (Synthes, Westchester, Pennsylvania, USA) for the grafting of non-unions [30] . Following the operative opening of this cavity, via the greater trochanter, suction tubing and 50 ml bladder syringe was used to collect the sample. In some patients with fracture non-union 10 ml of peripheral blood (PB) was also collected (n=5). Samples were transferred immediately into EDTA containing vacutainers (BD Biosciences) and transported to the laboratory.
Specimen processing:
Samples were processed under aseptic conditions and sample volumes in millilitres were recorded. The average sample volume for long bone fatty bone marrow aspirate was 12ml
(range 11-17ml); ICBM aspirate volume was always 10ml. A manual nucleated cell (NC) count was performed on every sample following red cell lysis in 0.4% acetic acid (Sigma, Gillingham, UK). In some experiments (n=4), the aspirated IM contents were left at room temperature for 1 hour, during which the fatty contents congealed leading to the formation of 'solid' and 'liquid'
phases. To physically separate these phases, samples were passed through a 70μm cell strainer (BD Biosciences). The resulting solid phase was digested using collagenase (Stem Cell
Technologies, Grenoble, France ) at 1:1 ratio w/v (final concentration = 0.125%), for 60 min at 37 C. Subsequently all fractions were used for CFU-F assay or initiation of in vitro MSC cultures.
In some experiments (n=7), mononuclear cells (MNCs) were isolated using Lymphoprep (Axisshield, Huntingdon, UK) and counted, as described previously [27] .
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CFU-F assay and MSC expansion:
CFU-F assay was performed as previously described [26] (Invitrogen, Paisley, UK). Adherent cells were cultured (37 C, 5% CO2) with half-media changes performed twice weekly. PB MNCs were seeded at 5x10 6 cell/dish and cultured similarly [31] .
Crystal violet staining was performed on the fourteenth day, as previously described [32] before scoring blindly.
Expansion was performed to produce sufficient cells to undertake trilineage differentiation and cell surface phenotyping in all fractions as previously described [32] . Cells were expanded until 80% confluency was attained (denoted as passage 0/P0), after which cells were trypsinised and passaged up to P3 [32, 33] . Population doublings (PDs) were calculated according to the following formula: PDs=log 2 (N cells at P3/CFU-F seeded) [33] .
Tri-lineage differentiation:
Passage-3 MSCs (n=4 donors) were induced towards osteogenesis, chondrogenesis and adipogenesis according to standard protocols [1, 32] . For osteogenesis, cells were seeded at a density of 3 x 10 4 /well in 3cm diameter wells (Corning Life Sciences) and cultured in low glucose DMEM with 10% FCS, supplemented with standard antibiotic mixture (100units/ml penicillin and 100µg/ml streptomycin) (all from Invitrogen), 100nM dexamethasone, 10mM β-glycerophosphate and 0.05mM ascorbic acid (all from Sigma), with twice weekly half-media changes. Alkaline phosphotase activity was assessed on day 14 post-induction, as previously
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described [32] . For adipogenesis, cells were seeded in 12-well plates at 1 x 10 5 cells/well and cultured in low glucose DMEM with 10% FCS, antibiotics, 10% horse serum (Stem Cell Technologies), 0.5mM isobutylmethylxanthine, 60µM indomethacin and 0.5µM hydrocortisone (all from Sigma). Cultures were stained on day 14 post-induction with oil-red-O, as previously described [27, 32] .
A 3D pellet culture model was used to induce chondrogenesis as previously described [32] with minor modifications. Briefly, pellets were formed in 1.5 ml micro-centrifuge tubes by centrifugation (650 g, 5 min) of 2.5x10 5 cells suspended in 1 ml of serum-free medium consisting of high glucose DMEM (Invitrogen), antibiotics, 40µg/ml L-proline, 1.5 mg/ml BSA, 4.7µg/ml linoleic acid, 1× insulin-transferrin-selenium, 50µg/ml L-ascorbic acid-2-phosphate, 100nM dexamethasone (all from Sigma) and 10ng/ml TGF-β3 (R&D Systems, Abbingdon, UK).
Full media changes were performed twice weekly and biochemical assessment performed at 21-days as previously described [34] with minor modifications. Briefly, pellets were digested for 18 hours at 60 C, with a papain digestion solution containing 100mM Sodium Phosphate Buffer supplemented with 5mM Na 2 EDTA , 10mM L-cysteine and 0.125mg/ml papain (all from Sigma).
DNA content was assessed using a Quant-iT™ PicoGreen ® dsDNA Reagent Kit (Invitrogen) and produced glycosaminoglycan (GAG) was measured using a Blyscan™ kit (Biocolor Life Sciences, Co Antrim, Ireland).
Surface phenotype of culture expanded MSCs:
Passage-3 MSCs (n=3 donors) were trypsinised and re-suspended at 
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CD19-PE (BD Biosciences), CD105 (Endoglin)-PE and CD90 (Thy1)-PE (Serotec). All antibodies were used at the manufacturers recommended concentrations with matched isotype controls (from Serotec). Dead/ dying cells were excluded from the analysis using DAPI (Sigma) and were normally less than 5%. Data were analysed on an LSRII flow cytometer equipped with DIVA software (BD Biosciences).
MSC enumeration:
The phenotypic identification of the 'ex-vivo MSC' using the CD45 -/low CD271 + phenotype was first described by our group using ICBMA [27, 28, 35] and has since been independently validated by others [29, 36, 37] . MSC enumeration was performed by staining the aspirated MNC fraction with CD45-FITC (Dako UK Ltd, Ely, UK), CD271-PE (Miltenyi Biotec) and 7-AAD, as previously described [28] . A minimum of 5x10 5 events were acquired and analysed using LSRII 
Extended phenotypic analysis of 'ex-vivo MSC' using 6-colour flow cytometry:
Bone marrow MNCs were isolated using Lymphoprep and cells were then re-suspended at 
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Statistics
Statistical analysis and graphing were performed using GraphPad Prism version 4 for Windows (San Diego, California, USA). Gaussian distribution could not be assumed given the number of samples and differences between donor-matched ICBMA and LBFBM groups were tested using
Wilcoxon signed ranks test. The differences in the MSC content between different patient groups were analysed using Mann-Whitney test. Significance was assumed when p<0.05.
RESULTS
Basic cellular characterisation of ICBM and LBFBM aspirates
A standard CFU-F assay was first performed to measure the MSC content of ICBM aspirates in three groups of orthopaedic patients and healthy controls (Table 1) . Consistent with previously reported findings [10] , high donor-to-donor variation was observed, potentially due to factors related to donor age [38] or a variable degree of dilution of ICBM sample with blood during the aspiration procedure [39] . No significant differences in CFU-F abundance in ICBMA were found between all three groups of orthopaedic patients and healthy controls (Table 1) hematopoietic progenitor cells and CD31+ endothelial/angiogenic cells [40] were not statistically different between the two sources ( Figure 1C and D) .
Resident MSCs were measured using CFU-F assay and flow cytometry for the CD45 -/low CD271 + cell population ( Figure 1E-I) . The frequency of CD45 low CD271 + cells was higher in LBFBM aspirate ( Figure 1E ). In correspondence, LBFBM aspirate contained higher numbers of CFU-Fs compared to ICBMA (median values 293 and 115 CFU-F/ml, respectively), however differences narrowly failed to reach statistical significance (p=0.0515, Figure 1F ). CFU-F dishes from a representative donor are shown on Figure 1G . A similar trend for the MSC increase in LBFBMA was observed following the measurements of CD45 -/low CD271 + cells/ml ( Figure 1H ). Flow cytometry data from a representative donor are shown on Figure 1I . It is noteworthy, that no CFU-Fs/MSCs were found in PB of patients with fracture non-unions (n=5). Based on these findings it is evident that LBFBM aspirates were not inferior to ICBMA in terms of the proportions of regenerative cells and MSCs per sample volume.
Extended phenotypic characterisation of uncultured MSCs in LBFBM aspirates
Although MSCs were found in similar proportions in LBFBM and ICBM aspirates, their functional and phenotypic characteristics could be altered in fatty environments. An extended phenotypic analysis of CD45 -/low CD271 + 'ex vivo' MSCs in LBFBM and ICBM aspirates was undertaken to identify any potential differences in surface receptor expression. The gating strategy for this analysis is shown in Figure 2A . CD73 (5' Ecto-nucleotidase) is a broadly-accepted MSC marker [1, 39] and it was expressed at similar levels on CD45 -/low CD271 + 'ex vivo' MSCs from both sources (~91%, n=3) ( Figure 2B ). The MSC markers CD105 (Endolgin) and CD90 (Thy1) were expressed at similar levels in LBFBM and ICBM aspirates ( Figure 2B ) whereas CD31 (PECAM-1), an endothelial cell marker, was negative. Finally, we investigated the expression of CD34 molecule on MSCs from ICBMA and LBFBM. This was based on recently-published evidence of
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CD34 being present on MSCs from lipoaspirates [41] . Consistent with our previous findings relating to ICBMA [27] , CD34 was absent on CD45 -/low CD271 + MSCs from both bone sources ( Figure 2B ). Overall, MSC marker expression levels were similar in LBFBM and ICBM aspirates and representative marker histograms are shown on Figure 2C . Therefore, based on the expression of 5 selected surface markers, CD45 -/low CD271 + cells from LBFBM aspirates had classical 'ex vivo' BM MSC phenotype, similar to ICBMA and different from lipoaspirates.
Phenotypic characterisation of MSC cultures generated from LBFBM and ICBM aspirates
Although MSC numbers and phenotypes were similar in ICBM and LBFBM aspirates, functional differences in MSCs could exist, due to their anatomical locations. We next compared growth and phenotypic characteristics of MSC cultures obtained from LBFBM and ICBM aspirates ( Figure 3 ).
No statistically significant differences were found in the growth rates, measured as days/PD up to P3, of ICBMA and LBFBM derived MSC cultures (median values of 2.36 and 2.44, respectively, Figure 3A ). Early-passage cultures (P3) from both sources had indistinguishable morphology ( Figure 3B ) and similar phenotypes, using an extended panel of 10 surface markers ( Figure 3C ).
The majority of cultured cells expressed MSC markers CD73, CD90 and CD105 and were negative for hematopoietic lineage cell markers as well as CD31 and CD34. Representative histograms are shown on Figure 3D . Altogether these data showed that LBFBM aspirates were similar to donor-matched ICBM aspirates in terms of growth and phenotypic characteristics of resident MSCs.
Differentiation potentials of MSCs derived from LBFBM and ICBM aspirates
To investigate tripotentiality, P3-MSC cultures derived from ICBM and LBFBM aspirates were placed in osteo-, adipo-and chondrogenic differentiation conditions (n=4 donors)( Figure 4 ). All cultures exposed to osteogenic induction conditions for 14 days contained polygonal cells
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
consistent with osteoblastic progression ( Figure 4A ). No obvious pattern of differences between in ICBM and LBFBM aspirates was documented in the proportions of alkaline-phosphatase positive cells ( Figure 4B ). Similar data were obtained for adipogenesis: all MSCs were able to produce Oil-Red positive mature adipocytes, with no apparent gross differences between the samples ( Figure 4C and D) . Chondrogenesis was performed using a classical pellet culture [27] and measured as accumulation of cartilage-specific proteoglycans per cell [34] . Similarly to osteo-and adipogenesis, no significant differences between ICBM-and LBFBM-derived pellets were found ( Figure 4E -G).
We next investigated whether any observed donor-to-donor differences could be attributed to the "in vitro age" of tested cultures (measured as total PDs at P3, i.e. prior to differentiation).
On average, MSCs from ICBM aspirates and LBFBM aspirates have both undergone 16PDs, with no apparent correlations being found between the "in vitro age" and functional outcomes for individual cultures. Overall, all these functional data showed that LBFBM MSCs were osteogenic and chondrogenic at the levels comparable, and often superior, to ICBM MSCs, making them suitable for therapeutic bone repair applications.
Enhanced release of MSCs from LBFBM aspirates using an enzymatic digestion technique
Following 1 hour storage at RT, fatty components of LBFBM aspirates tend to congeal, resulting in the formation of fatty solid aggregates. To extract increased numbers of MSCs from this material, the solid aggregates from LBFBM aspirates were exposed to a brief enzymatic digestion ( Figure 5 ).
Although a trend for higher numbers of CFU-F/ml was found in the solid phase ( Figure 5A and B), the differences were not statistically different between liquid and solid phases. Similar findings were observed for percentages of CD45 -/low CD271 + cells ( Figure 5C and D). Fatty solid
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aggregates contributed to ~23% of total sample volume ( Figure 5E ) and contained the equivalent of ~30% of the total sample's CFU-Fs ( Figure 5F ). At room temperature these MSCs are "trapped" in the solid fatty aggregate, but were easily released by a brief enzymatic digestion. Alternatively, samples could be kept at body temperature (or at 37 C in the laboratory) to avoid the loss of MSCs due to solidification of fatty components.
DISCUSSION
The conversion of red marrow to yellow marrow is a physiological dynamic process that starts in infancy at the terminal phalanges and progresses in a centripetal direction [42] , so that by adulthood the diaphyses of long-bones are almost entirely populated by yellow, fatty bone marrow [43] . MSCs are commonly harvested from long-bones in rat [19] , mouse [20] , rabbit [21, 23] and porcine [24, 25] models. In contrast to human subjects, the description of a yellow fatty appearance of the long bone marrow in these reports is rarely mentioned, which may be partly due to the fact that the majority of animal models are sacrificed at a juvenile stagepossibly prior to red marrow conversion. The aim of this study was to comprehensively assess human LBFBM as a source of MSCs for bone repair applications and to compare it with ICBM aspirate.
Using donor-matched samples, we have found that LBFBM was non-inferior to ICBMA in terms of its cellularity, basic cellular composition and the proportions of MSCs. In fact, LBFBM had higher proportions of CFU-Fs compared to ICBMA (2.5-fold). These differences narrowly failed to reach statistical significance but in a larger scale study they may do so. Despite the fatty environment within LBFBM cavity, LBFBM-derived MSCs possessed the classical MSC phenotype, before and after culture, arguing for good preservation of their undifferentiated status. Furthermore, LBFBM-derived MSCs had similar growth characteristics and multipotential properties as their ICBMA counterparts. This is of interest as MSCs from other adipogenic sources have often been shown to be inferior to ICBMA in forming bone [12, 13] and this may be related to the intra-osseous location of MSCs in long-bone cavities.
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Numerous literature reports describing the presence of CFU-F/MSCs in connective adipose tissues, including lipoaspirates, document MSC frequencies that are considerably higher than in BM aspirates (at least 2 orders of magnitude) (reviewed in [44] ). In comparison, the abundance of MSCs in "yellow" fatty marrow aspirates observed in our study appears to be relatively minor (only a 2-5 fold higher than in classical "red" marrow aspirates). Given the unique function of adipocytes in the marrow [45] [46] [47] and the different metabolic functions of fat in different depot sites [47] , our data indicate that the MSC pool size in "fatty tissues" is clearly site-specific.
Variations in MSC function have been documented for different types of bone: orofacial, axial and appendicular [48] and different depots of fat: arm , flank, thigh and abdomen [49] . The heterogeneity of MSCs resident within seemingly same type of tissues but located in different anatomical areas may be explained by varying local demands for tissue turnover and mechanical loads [48] . Additionally, the MSC topography in diverse human tissues has been described as primarily perivascular [50, 51] and it is possible that lower MSC frequency in fatty marrow as opposed to subcutaneous fat may be also related to blood vessel density as suggested previously for human synovium [52] and equine adipose tissue [53] .
The fact that LBFBM-derived cultured MSCs were able to effectively differentiate towards osteoblasts and chondrocytes in vitro provided strong evidence that minimally expanded LBFBM-derived MSCs can be used as cell therapy for fracture non-unions. Furthermore, high numbers of CD45 -/low CD271 + cells present in LBFBM samples (up to 67,000, median 43,620 in 10ml) suggested that their direct injection, in a one-stage procedure, may be possible without prior cell-culture. One previous study has showed that a dose of 50,000 uncultured MSCs from ~300ml of ICBMA was efficacious following injection into non-union fracture sites [10] . A lower volume of LBFBM would therefore be sufficient to obtain a similar number of MSCs. Uncultured
MSCs could be effectively concentrated using magnetic beads against the CD271 molecule, based on our findings showing that the proportions of CD45 -/low CD271 + cells closely reflected that of CFU-Fs [28] .
The findings from this study also offer additional cellular mechanism to explain efficient bone healing process following LB fracture. In summary, this study demonstrates that the femoral IM cavity represents a depot of MSCs which could be used for autogenous/allogeneic use and can be harvested using 'low-tech'
techniques for a variety of commonly performed operations including trauma surgery and total hip replacement. The IM cavities of long-bones, in which the FBM resides, are also readily accessible by the orthopaedic surgeon during lower-limb arthroplasty/nailing of long-bone fractures, with the marrow contents requiring removal prior to prosthesis insertion.
Enumeration of MSCs from LBFBM is possible using the CD271 + CD45 low phenotype and their concentration could be achieved with the use of magnetic beads against the CD271 molecule.
The use of freshly-isolated or minimally-expanded LBFBM-derived MSCs could therefore have important scientific and economic benefits in tissue engineering and treatment of fracture nonunions. 
